HCA Healthcare, Inc. (HCA) Stock Price & Analysis
HCA Healthcare, Inc. (HCA) closed at USD 467.31 on Thursday, October 22, 2026, up 1.72% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 459.4; the Oct 22, 2026 session ranged USD 456.18–467.31 on volume of 872,740 shares. Market capitalization is $101.17B, with a 52-week range of USD 353.99–556.52 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 09:26 UTC.
Also available as compact Markdown for AI agents: nexqual.com/HCA.md
Key facts (HCA)
- Last four reported quarters (through Jun 30, 2026): revenue $78.0B, net income $6.84B (8.8% margin), free cash flow $6.00B (SEC filings).
- Valuation: P/E 14.8x (avg 14.8x at the last 3 fiscal year-ends), net debt $48.7B.
- 5 of 80 tracked superinvestors hold HCA (13F, Q2 2026): 0 new, 4 added, 1 reduced, 0 unchanged.
- Analysts: Hold (mean 2.50 on a 1–5 scale) (26 analysts), mean target USD 460.59 (range 380–579).
- Total return with dividends: 1Y +6.9% vs S&P 500 +14.9%; 5Y +92.5% vs S&P 500 +80.3%.
- Next earnings: 2026-10-27, EPS estimate USD 6.63, revenue estimate $19.3B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (HCA)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $58.8B | $60.2B | $65.0B | $70.6B | $75.6B | $78.0B |
| Net income | $6.96B | $5.64B | $5.24B | $5.76B | $6.78B | $6.84B |
| EPS (diluted) | $21.16 | $19.15 | $18.97 | $22.00 | $28.33 | — |
| Free cash flow | $5.38B | $4.13B | $4.69B | $5.64B | $7.69B | $6.00B |
| Net margin | 11.8% | 9.4% | 8.1% | 8.2% | 9.0% | 8.8% |
| Revenue growth | +14.0% | +2.5% | +7.9% | +8.7% | +7.1% | — |
| Cash + short-term investments | $1.55B | — | — | $1.93B | $1.04B | — |
| Total debt | $34.6B | $38.1B | $39.6B | $43.0B | $46.5B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (HCA)
P/E 14.8x · P/S 1.3x · EV/Sales 1.9x · P/FCF 16.9x · FCF yield 5.93% · Earnings yield 6.76% · Dividend yield (paid, TTM) 0.67% · Buyback yield (TTM) 8.59% · Net debt $48.7B · EV $150B
P/E at fiscal year-ends: Dec 2025 16.5x, Dec 2024 13.6x, Dec 2023 14.3x.
Superinvestors (SEC 13F-HR, Q2 2026) (HCA)
5 of 80 tracked investors hold HCA. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| First Eagle Investment | First Eagle Investment Management | 2.14% | $1.28B | Added +1.3% |
| Thomas Gayner | Markel Group | 0.25% | $32.9M | Added +2.4% |
| Richard Pzena | Pzena Investment Management | 0.11% | $37.7M | Added +2.5% |
| Bill Nygren | Oakmark Funds | 0.08% | $60.1M | Reduced -2.6% |
| Glenn Greenberg | Brave Warrior Advisors | 0.04% | $1.9M | Added +262.6% |
Analysts (HCA)
Consensus Hold (mean 2.50 on a 1–5 scale), 26 analysts; mean target USD 460.59 (low 380, high 579).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-12 | TD Cowen | Target raised | Buy | $431 → $460 |
| 2026-10-07 | RBC Capital | Target raised | Outperform | $435 → $496 |
| 2026-09-23 | BMO Capital | Initiated | Outperform | $495 |
| 2026-09-18 | Leerink Partners | Maintained | Outperform | $492 |
| 2026-09-08 | RBC Capital | Reiterated | Outperform | $435 |
| 2026-08-20 | JP Morgan | Target lowered | Neutral | $490 → $425 |
| 2026-08-03 | Wells Fargo | Target raised | Equal-Weight | $369 → $381 |
| 2026-07-28 | Goldman Sachs | Target lowered | Buy | $558 → $485 |
| 2026-07-28 | Mizuho | Target lowered | Outperform | $525 → $475 |
| 2026-07-27 | UBS | Target lowered | Buy | $635 → $579 |
| 2026-07-27 | Morgan Stanley | Target lowered | Underweight | $425 → $380 |
| 2026-07-27 | RBC Capital | Reiterated | Outperform | $435 |
Total return (dividends reinvested) (HCA)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +6.9% | +92.5% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +6.9% | +14.0% |
| Volatility (annualized) | 31.2% | 29.9% |
| Max drawdown | -33.6% (Mar 2026→Jun 2026) | -35.4% (Mar 2022→Jul 2022) |
HCA analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $6.63 | $7.00 | -5.3% | $19.32B | 20 |
| Next quarter (ends Dec 2026) | $8.06 | $8.11 | -0.6% | $19.84B | 20 |
| Current fiscal year (ends Dec 2026) | $29.49 | $29.92 | -1.5% | $78.51B | 20 |
| Next fiscal year (ends Dec 2027) | $31.99 | $32.74 | -2.3% | $81.57B | 23 |
Key Statistics (as of October 23, 2026 at 09:26 UTC)
| Price | USD 467.31 |
|---|---|
| Change | ▲ 1.72% (up) |
| Previous Close | USD 459.4 |
| Open | USD 460.89 |
| Day Range | USD 456.18 – 467.31 |
| 52-Week Range | USD 353.99 – 556.52 |
| Volume | 872,740 shares |
| Market Cap | $101.17B |
| Exchange | NYQ |
Technical Analysis (HCA)
Nexqual's technical model rates HCA "STRONG BUY" based on 5 bullish and 0 bearish signals across 127 daily candles, as of October 23, 2026 at 09:26 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 66.14 (neutral) |
| vs SMA50 | Above (USD 430.37) |
| MACD | 10.78 (positive) |
Analyst Ratings (HCA)
Wall Street analysts rate HCA "Hold" based on 26 analysts, with a mean price target of USD 460.59 (range USD 380–579), per Nexqual as of October 23, 2026 at 09:26 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 26 |
| Mean Target | USD 460.59 |
| High Target | USD 579 |
| Low Target | USD 380 |
| Buy / Hold / Sell | 15 / 9 / 2 |
Earnings (HCA)
| Next Earnings Date | 2026-10-27 |
|---|---|
| EPS Estimate | USD 6.63 |
| Revenue Estimate | $19.32B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 7.59 vs est 7.5 ▲ beat |
| 2026-03-31 | USD 7.15 vs est 7.13 ▲ beat |
| 2025-12-31 | USD 8.01 vs est 7.48 ▲ beat |
| 2025-09-30 | USD 6.96 vs est 5.73 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:26 UTC.
Financials & Fundamentals (HCA)
| Total Revenue | $78.01B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +8.70% |
| Gross Margin | +42.58% |
| Operating Margin | +15.16% |
| Profit Margin | +8.77% |
| Current Ratio | 0.99 |
| Total Cash | $1.13B |
| Total Debt | $51.55B |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $6.00B (7.7% of revenue) |
Source: Nexqual, October 23, 2026 at 09:26 UTC.
Financial Health Score (HCA)
Nexqual rates HCA Healthcare, Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 09:26 UTC.
| Growth | Solid — Revenue +7% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 43%, operating 15% (last 12 months) |
| Balance Sheet | Mixed — $1.01B cash and investments vs $49.7B debt (Jun 2026, SEC) |
| Cash Flow | Solid — FCF $6.00B (last 4 quarters to Jun 2026, SEC), 8% margin |
| Efficiency | Mixed — No data |
Ownership (HCA)
| Insider Ownership | +16.61% |
|---|---|
| Institutional Ownership | +78.68% |
| Shares Outstanding | 216.50M |
| Float | 144.32M |
| Short % of Float | +3.47% |
Source: Nexqual, October 23, 2026 at 09:26 UTC.
Leadership (HCA)
HCA Healthcare, Inc. is led by Samuel N. Hazen, CEO & Director, per Nexqual as of October 23, 2026 at 09:26 UTC.
| CEO & Director | Samuel N. Hazen |
|---|---|
| CFO & Executive VP | Michael A. Marks |
| Executive VP & COO | Jon Mack Foster |
| Founder & Chairman Emeritus | Thomas F. Frist Jr. |
| Vice President of Investor Relations | Frank George Morgan C.F.A. |
Major Backers & Investors (HCA)
Notable institutional backers of HCA Healthcare, Inc. include Sanders Capital, LLC, Wellington Management, Growth Fund of America, according to Nexqual as of October 23, 2026 at 09:26 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Sanders Capital, LLC | 4.08% |
| Wellington Management | 2.17% |
| Growth Fund of America | 1.82% |
| First Eagle Investment Management, LLC | 1.52% |
| Morgan Stanley | 1.19% |
| Goldman Sachs | 1.14% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 6.01% |
| Vanguard Group | 5.93% |
| State Street | 3.45% |
| Geode Capital | 1.69% |
Source: Nexqual, October 23, 2026 at 09:26 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| THC | Tenet Healthcare Corporation | USD 270.63 | ▲ 0.56% |
| EHC | Encompass Health Corporation | USD 126.01 | ▲ 4.6% |
| DVA | DaVita Inc. | USD 186.1 | ▲ 5.25% |
| FMS | Fresenius Medical Care AG | USD 22.23 | ▲ 3.11% |
| UHS | Universal Health Services, Inc. | USD 188.13 | ▲ 2.88% |
| ENSG | The Ensign Group, Inc. | USD 178.35 | ▲ 2.88% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:26 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt